Low-cost compounded GLP-1s, shadowed by a federal warning letter
Two things dominate Lumimeds reviews: a monthly figure that undercuts most compounded GLP-1 programs, and a warning letter the FDA issued to the company on September 9, 2025 over how its GLP-1 injections were promoted. The tracked entry point is $189 a month. Homepage teaser “From $89/month” / “as low as $89/mo” is actually the 12-Month Subscription plan (48 injections prepaid, renews at $1,068 every 47 weeks = $89/mo divided). The true month-to-month plan with no long-term commitment (“No long-term commitment required”, renewed monthly) is $189/mo for compounded semaglutide. Tirzepatide monthly no-commitment is $249, NAD+ monthly no-commitment is $199
The catalogue is narrow and honest about what it is: compounded semaglutide and compounded tirzepatide, sold cash only, with no FDA-approved brand route and no oral tablet on record. That combination suits a patient who has already decided on a weekly GLP-1 injection and wants the cheapest recurring charge they can find. It works far less well for anyone who wants an FDA-approved product, insurance billing, or a documented lab and titration protocol they can read before paying.
The trade-off is unusually clear here, and worth naming before anything else. You are buying a medicine that the FDA has not reviewed for safety, effectiveness or quality, from a company with a federal warning letter on the public record, at a price that is genuinely low.
What the monthly charge buys, and what it leaves out
Billing runs as a monthly subscription rather than a charge per visit. That $189 entry rate is the lowest recurring monthly figure a new cash-pay patient can start on, and it is the number the price panel on this page tracks. We desk-verify advertised self-pay rates against the provider’s live site and re-check them on a monthly cycle, because compounded GLP-1 sellers change their sheets often.
Two mechanics decide what you actually pay. First, medication choice: a semaglutide plan and a tirzepatide plan do not cost the same, and the entry figure is the floor of the sheet, not the tirzepatide rate. Second, prepayment: the lowest advertised rates depend on committing to several months up front. Prepaying converts a cancellable monthly charge into money you have already handed over, which matters more than usual when the company carries a federal warning letter and public complaints about fulfilment.
Because this is a cash-pay service, insurance is not billed and no prior authorisation stands between you and a first shipment. That removes weeks of paperwork. It also means nothing you spend counts toward a deductible, and none of it is reimbursed. If you are weighing a cheap compounded subscription against a brand-name plan your insurer might partly cover, run both over twelve months rather than one.
Annualising the charge is the fastest way to see what a GLP-1 subscription really costs you.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
Before you pay, get three things in writing: what the monthly figure includes, what bills separately, and how cancellation works. Ask whether needles, syringes, alcohol swabs and shipping are inside the plan or added at checkout. Ask whether a dose increase changes the monthly charge. Ask how many days before the renewal date you must cancel, and whether unused prepaid months are refundable. Category pricing shifts fast, so it is worth reading the current comparison on our GLP-1 telehealth guide alongside this review.
Compounded semaglutide: the entry track
How the drug works
Semaglutide is a GLP-1 receptor agonist, a medicine that copies a gut hormone your body already makes. It slows how fast the stomach empties, blunts appetite signals in the brain, and improves blood sugar control. The FDA-approved versions are Ozempic for type 2 diabetes and Wegovy for chronic weight management, both once-weekly injections under the skin. The FDA maintains a plain-language page on medications containing semaglutide.
Dosing and titration on the approved schedule
The approved weight-management brand starts at 0.25 mg once weekly and steps up roughly every four weeks, reaching a 2.4 mg maintenance dose. The slow ramp exists to limit nausea, not to pad the timeline. Compounded products do not have to follow that schedule, and vial concentrations differ between pharmacies, which is the single most common source of confusion for new patients. Ask Lumimeds directly: what strength is in the vial, how many units make my dose, and on what week does the dose increase.
Side effects most people meet
Nausea, vomiting, diarrhoea, constipation, stomach pain and tiredness are the usual complaints, and they cluster in the first days after each dose increase. Most fade. Dehydration from repeated vomiting or diarrhoea is the practical risk that sends people to urgent care, so fluids matter. Serious but less common problems include pancreatitis, gallbladder disease and kidney injury. Patient-facing detail sits on the MedlinePlus semaglutide injection page.
What compounding changes
A compounded copy is mixed by a pharmacy rather than manufactured under an approved application. The FDA does not review compounded drugs for safety, effectiveness or quality, and says so plainly in its compounding questions and answers. Potency, sterility and labelling therefore rest on the individual pharmacy. That is why the pharmacy question below is not a technicality.
Who this track suits
People starting their first GLP-1, people who tolerated semaglutide before and lost access when brand supply or coverage changed, and people whose budget sets the ceiling. Our compounded versus brand semaglutide breakdown covers the differences in more depth.
Compounded tirzepatide: the stronger option on the sheet
Compounded Semaglutide vs. Compounded Tirzepatide
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors targeted | GLP-1 | GLP-1 + GIP |
| Approved brands | Ozempic, Wegovy | Mounjaro, Zepbound |
| Starting dose (brand schedule) | 0.25 mg weekly | 2.5 mg weekly |
| Maintenance dose (brand schedule) | 2.4 mg weekly | Up to 15 mg weekly |
| Monthly cost on this plan | Entry-level (lower) | Higher than semaglutide |
| Common reason to choose | First GLP-1, budget ceiling | Semaglutide stall or intolerance |
Why a dual agonist behaves differently
Tirzepatide acts on two hormone receptors, GIP and GLP-1, rather than one. The approved brands are Mounjaro for type 2 diabetes and Zepbound for chronic weight management, both weekly injections. The FDA’s approval announcement for chronic weight management sets out the approved use. Many patients move to tirzepatide when semaglutide stalls or when nausea on semaglutide never settles.
The approved titration pattern
Brand tirzepatide starts at 2.5 mg weekly for four weeks, moves to 5 mg, then increases in 2.5 mg steps at four-week intervals up to a 15 mg maximum. Again, a compounded vial is not obliged to match that. Ask whether your plan steps up automatically, whether a clinician signs off on each increase, and what happens if you need to hold a dose for a month.
Side effects and monitoring
The gastrointestinal profile mirrors semaglutide: nausea, diarrhoea, vomiting, constipation, reflux. Appetite suppression can be strong enough that protein and fluid intake slip, which costs muscle rather than fat. Ask about baseline weight, blood pressure and, if you have diabetes or prediabetes, an A1c. Anyone taking insulin or a sulfonylurea needs a plan for low blood sugar, because adding a GLP-1 raises that risk.
What to check before you pick this track
Across compounded programs, tirzepatide almost always carries a higher monthly charge than semaglutide, and the entry figure tracked here is the floor of the plan sheet rather than the tirzepatide rate. Confirm the tirzepatide figure at checkout, and confirm whether it changes as your dose rises. Our tirzepatide dosing and side effects page covers what the label expects.
Is Lumimeds FDA-approved? The honest answer
No telehealth company is FDA-approved, because the agency approves drugs and devices, not clinics. The question people are really asking is whether the injections are approved products, and they are not. Compounded semaglutide and compounded tirzepatide are copies of approved molecules made by a pharmacy, outside the approval system.
That distinction carried less weight while brand supply was short, because compounders were permitted more latitude during shortages. The FDA has since declared those shortages resolved and has narrowed what may be copied. The agency also publishes a warning about unapproved GLP-1 drugs used for weight loss, including reports of dosing errors where patients drew up ten times the intended amount after confusing units with milligrams. If you buy a compounded vial from any seller, have someone walk you through the exact unit count on your syringe.
None of this makes compounded medicine automatically unsafe. It does mean the quality assurance that sits behind an approved product is replaced by the standards of one pharmacy, and you are entitled to know which one.
Who prescribes, and how the medical side runs
A prescription medicine still requires evaluation by a licensed prescriber, and that applies here as it does anywhere. What is worth pinning down is the format. Ask whether your evaluation is a live video visit, a phone call, or a written questionnaire reviewed asynchronously by a clinician, and ask whether you can message that clinician later without paying again.
There is one structural detail worth knowing: no Surescripts e-prescribing connection appears on the record for this provider. Practically, that means you should expect the prescription to flow through the platform’s own pharmacy channel rather than being routed to your local retail pharmacy. If your plan was to have a script sent to the chemist down the road, this is not the service for it.
| Track | What it is used for | Form and schedule | Dose pattern to confirm | Monitoring worth asking about |
|---|---|---|---|---|
| Compounded semaglutide | Weight management | Weekly injection under the skin | Whether doses step up on a fixed timetable and at what strength per vial | Weight, blood pressure, thyroid and pancreatitis history, pregnancy plans |
| Compounded tirzepatide | Weight management | Weekly injection under the skin | Whether increases follow the four-week brand pattern and how the charge changes | Weight, A1c if diabetic, low blood sugar risk on insulin or sulfonylureas |
Nothing in the public record sets out a required lab panel or a fixed follow-up cadence, so treat that as a question rather than an assumption. A program that never checks in after the first prescription is cheaper for a reason. Our scoring methodology explains how clinical rigour is weighted against price.
Signing up: the sequence to expect
Step 1: Create the account
Registration happens on the website, and the same login carries your order history, messages and refills afterwards. Use an email you check, because shipping notices and dose instructions land there.
Step 2: Complete the medical intake
Expect questions on height, weight, medical history, current medicines, allergies, thyroid and pancreatic history, and pregnancy plans. Answer them accurately even where a truthful answer might disqualify you. The intake is the only clinical safety net in a cash-pay model.
Most weight-management programs screen on body mass index alongside other conditions, so it helps to know your number before you start the form.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
Step 3: Clinician review
A licensed prescriber reviews your answers and decides whether a GLP-1 is appropriate, and at what starting dose. Ask for the clinician’s name and licence state if it is not shown to you.
Step 4: Pay and choose your term
This is the decision point on prepayment. A single month costs more per month but leaves you free to stop after one shipment. A multi-month term lowers the monthly figure and removes that exit.
Step 5: Pharmacy fill and delivery
The compounding pharmacy prepares and ships the vial or pen with supplies. Ask for the pharmacy’s name and the state it is licensed in, and check that name against the state board of pharmacy register. A seller that will not name the pharmacy filling your injection has answered the question by refusing.
On coverage, this is a nationwide-facing telehealth service rather than a clinic network, but state availability for compounded GLP-1 prescribing shifts with state law. Confirm your state is served before you pay, not after. If it is not, our telehealth provider directory is the faster route to one that is.
Refills, messaging and support after the first box
Support here runs through the account portal and email rather than a clinic phone tree. Public sentiment on responsiveness is broadly positive, which is the strongest thing this provider has going for it outside the price. Reviewers on Trustpilot mention quick replies and straightforward ordering.
Refill reliability is the softer spot. Community threads describe delays and fulfilment problems, and compounded supply chains are more fragile than brand ones because they depend on a single pharmacy’s stock of active ingredient. The practical protection is timing: reorder a fortnight before you run out rather than in your final week, so a delay costs you patience instead of a missed dose.
Set an escalation plan in advance. Ask what the response window is for a clinical question, who answers it, and what number or channel to use if a shipment arrives damaged, warm, or wrong. Ask what happens if you have a reaction and need to speak to a prescriber the same day. If the answer is a general inbox, know that going in.
Privacy and what happens to your health data
Intake forms for weight-loss telehealth collect more than most people expect: weight history, mental health notes, medication lists, sometimes photographs. Before you submit, read the notice of privacy practices and the terms rather than clicking through them.
Four things are worth checking specifically. Whether the clinical side operates under HIPAA and where the consumer app or website data sits outside that scope. What marketing consent you grant at signup, including text messages and email. Whether advertising or analytics trackers on the checkout share data with third parties. And how you request deletion of your record if you cancel. The FDA action against this company concerned promotion, which is a reminder that marketing and clinical functions can sit closer together than a patient assumes.
The trust and safety record, read straight
Start with the point in the company’s favour. Lumimeds holds LegitScript certification, the screen that major advertising platforms require before a healthcare seller can run paid ads. It involves checks on licensing and regulatory posture, and plenty of grey-market GLP-1 sellers do not have it. You can confirm any company’s status through the LegitScript certification lookup.
Now the point against. On September 9, 2025 the FDA issued a warning letter to Lumimeds, catalogued as MARCS-CMS 716510, concerning claims made for its GLP-1 injections. Warning letters are the agency’s formal notice that it considers conduct to violate federal law, and they are published in full. Read it yourself rather than taking any summary on trust, including this one: the FDA warning letter to Lumimeds is public.
What that letter does and does not tell you matters. It concerns how the injections were described in promotion. It is not a finding about any individual patient’s product, and it is not a recall. It does show a regulator taking issue with the company’s claims, and it is the reason the legitimacy question follows the brand around search results.
On transparency, the pricing is published up front rather than hidden behind a consultation, which is better practice than a good share of the category manages. The gaps are elsewhere: the compounding pharmacy, the refund window and the follow-up schedule are the details to demand in writing before you commit money.
Safety lines worth knowing before your first injection
Both molecules carry a boxed warning, the FDA’s most serious label warning, based on thyroid C-cell tumours seen in rodents. The approved labels say these drugs should not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. That history is a hard stop, not a discussion point, and it should be disclosed on the intake form.
Other situations that need a clinician’s judgement rather than a checkout: a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, diabetic retinopathy, kidney disease, or an eating disorder. Tell any surgeon or anaesthetist that you take a GLP-1, because delayed stomach emptying raises aspiration risk during sedation.
Pregnancy is its own category. These medicines are not for use in pregnancy, and the approved weight-management label advises stopping at least two months before trying to conceive. GLP-1s can also reduce how well oral contraception is absorbed in some patients, so ask about backup contraception.
Call a clinician promptly for severe or persistent abdominal pain that radiates to the back, ongoing vomiting, signs of dehydration, yellowing of the skin or eyes, or a lump or swelling in the neck with hoarseness or trouble swallowing. Do not increase your own dose to speed up results.
The patient this fits, and the one who should look elsewhere
This works for a cost-driven, self-directed patient. Someone who has read the compounding trade-off, has no thyroid or pancreatic red flags, wants a weekly injection at the lowest recurring charge available, and is comfortable managing a mostly asynchronous service. Someone who would rather start now on cash than spend six weeks fighting an insurer.
Look elsewhere if you want an FDA-approved product with a manufacturer behind it, if you need insurance billed, if you take insulin or a sulfonylurea and want close monitoring, if you have a complicated medical history, or if a regulator’s warning letter on the file is a dealbreaker for you. It is a reasonable dealbreaker. Look elsewhere too if you want an oral alternative or a program that publishes its lab and follow-up requirements, since neither appears on this provider’s record.
Questions to ask before you pay, and what to ask the provider you are leaving
Questions to Ask Lumimeds Before You Pay
- Which pharmacy compounds my medication, and in which state is it licensed?
- What strength is in the vial, and how many units equal my prescribed dose?
- Does the monthly charge rise as my dose increases?
- What is included in the plan: needles, swabs, shipping, follow-up messaging?
- How many days before renewal must I cancel, and are prepaid months refundable?
- Who is my prescriber, and how do I reach them about a side effect?
- Which pharmacy compounds and ships my medication, and in which state is it licensed?
- What strength is in the vial, and how many units equal my prescribed dose?
- Is the monthly figure fixed as my dose increases, or does it rise?
- What is included: needles, swabs, shipping, follow-up messaging?
- How many days before renewal must I cancel, and are prepaid months refundable?
- Who is my prescriber, and how do I reach them about a side effect?
If you are switching from another program, ask your current one for a copy of your records and your exact current dose in milligrams, not in units, and check whether cancelling immediately forfeits a shipment you have already paid for. Time the switch so your last dose from the old supplier overlaps the first from the new one. Our cost calculators will run your numbers across both before you commit.
Reputation check
Public sentiment splits cleanly, and Lumimeds reviews land in two very different places depending on where you read them. The Trustpilot profile for lumimeds.com shows a TrustScore of 4.5, with reviewers pointing to fast ordering and responsive customer service. That is a real signal about day-to-day dealings with the company.
Against it sits the federal record. The FDA warning letter dated September 9, 2025 ranks near the top of results for the company name, and it drives most of the legitimacy searching around the brand. A published warning letter is a documented regulatory event, not a rumour, and it will not disappear from the record because the customer service is good.
Community discussion is harsher in places. A thread in the r/tirzepatidecompound subreddit criticises service quality and the way the multi-month deals are structured. Forum posts are anecdotal and skew toward people with a grievance, so treat them as questions to raise rather than proof of a pattern. Read together, the record describes a low-cost compounded GLP-1 seller that many customers find easy to deal with, carrying a federal warning letter about how those injections were promoted.
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.